<DOC>
	<DOCNO>NCT01339975</DOCNO>
	<brief_summary>Despite novel treatment option , Renal Cell Carcinoma ( RCC ) characterize constant increase mortality consequently require important involvement translational research . The aim study evaluate interest CXCL4 , CXCL4L1 CXCR3 biomarkers localize , locally advanced metastatic RCC . Indeed chemokines show anti-angiogenic anti-tumor property experimental model may particularly interesting prognostic predictive purpose .</brief_summary>
	<brief_title>Level Expression Prognostic Value CXCL4 , CXCL4L1 CXCR3 Renal Cell Carcinoma</brief_title>
	<detailed_description>Based physiopathological rationale , use RCC-directed antiangiogenic therapy clinical practice lead conclusive result make RCC particularly well-suited tumor type study factor involve angiogenic process . Furthermore intensive use target therapy clinical practice raise new question management . Therefore identification new molecular biomarkers important : - improve precision prognostic model currently base clinical , biological histopathological variable - identify high risk patient could benefit adjuvant treatment closer postoperative follow-up - predict response antiangiogenic therapy therefore identify drug likely effective within ever increase pharmacopeia - follow therapy precisely possible , predict attest disease progression justify therapeutic modification Low CXCL4 , CXCL4L1 CXCR3 tumor expression level associate bad prognosis factor RCC . Consequently interest RCC worth evaluate , two subgroup : Localized / locally advance renal cell carcinoma Metastatic renal cell carcinoma .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<criteria>Patients diagnose localize , locally advanced metastatic Renal Cell Carcinoma : radical partial nephrectomy treat RCCdirected target therapy Patients sign date informed consent form investigator 18 year old</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Renal Cell Carcinoma</keyword>
	<keyword>Nephrectomy</keyword>
	<keyword>Antiangiogenics</keyword>
	<keyword>Chemokines</keyword>
	<keyword>Prognostic value</keyword>
	<keyword>Carcinoma</keyword>
	<keyword>Carcinoma , Renal Cell</keyword>
	<keyword>Kidney Neoplasms</keyword>
	<keyword>Kidney Diseases</keyword>
	<keyword>Neoplasms , Glandular Epithelial</keyword>
	<keyword>Neoplasms Histologic Type</keyword>
	<keyword>Neoplasms</keyword>
	<keyword>Adenocarcinoma</keyword>
	<keyword>Urologic Neoplasms</keyword>
	<keyword>Urogenital Neoplasms</keyword>
	<keyword>Neoplasms Site</keyword>
	<keyword>Urologic Diseases</keyword>
	<keyword>Adjuvants , Immunologic</keyword>
	<keyword>Physiological Effects Drugs</keyword>
	<keyword>Pharmacologic Actions</keyword>
	<keyword>Biomarkers</keyword>
	<keyword>Targeted therapy</keyword>
	<keyword>Surgery</keyword>
</DOC>